Ferring and Blackstone Life Sciences Invest Over $570 Million USD in Novel Gene Therapy for Bladder Cancer Patients
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
- Ferring launches new company FerGene, with a focus on the global development and US commercialization of nadofaragene firadenovec, for high-grade, Bacillus Calmette-Gu?rin unresponsive, non-muscle invasive bladder cancer patients
- Blackstone Life Sciences will invest $400 million USD and their expertise to accelerate the future development and commercialization of nadofaragene firadenovec, an investigational gene therapy
- The FDA has accepted the Biologics License Application (BLA) for filing and granted Priority Review for nadofaragene firadenovec
- Phase 3 results to be presented at Society of Urologic Oncology 20th?Annual Meeting in Washington DC on December 5, 2019